MEDIVATION, INC. Forms 3, 4 and 5: Other
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 15 rows, 15 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2016-09-28: Reporting owner Machado Patrick; Form 4; Security Stock Appreciation Rights; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2016-09-28: Reporting owner Hung David; Form 4; Security Stock Appreciation Rights; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2016-09-28: Reporting owner Hirmand Mohammad; Form 4; Security Stock Appreciation Rights; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2015-10-01: Reporting owner Hirmand Mohammad; Form 3; Security Stock Appreciation Rights; Transaction Holding.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2016-09-28 | Machado Patrick Director | 4 | Stock Appreciation Rights Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −222,800 0 owned after | $12.20 exercise price | 2016-09-30 | |
| 2016-09-28 | Hung David Director, Officer (President and CEO) | 4 | Stock Appreciation Rights Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −534,400 0 owned after | $12.20 exercise price | 2016-09-30 | |
| 2016-09-28 | Hirmand Mohammad Officer (Interim Chief Medical Officer) | 4 | Stock Appreciation Rights Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −58,800 0 owned after | $11.60 exercise price | 2016-09-30 | |
| 2015-10-01 holding as of filing | Hirmand Mohammad Officer (Interim Chief Medical Officer) | 3 | Stock Appreciation Rights Derivative · Direct | Holding | $11.60 exercise price | 2015-10-01 | ||
| 2013-02-04 holding as of filing | FALBERG KATHRYN E Director | 3 | No securities held. Non-derivative · Direct | Holding | 0 owned after | no price filed | 2013-02-04 | |
| 2012-10-03 | Machado Clarence Patrick Officer (Chief Business Officer and CFO) | 4 | Common Stock (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,100 88,832 owned after | $6.74 exercise price | 2012-10-03 | |
| 2011-12-09 | Machado Clarence Patrick Officer (Chief Business Officer and CFO) | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +55,700 55,700 owned after | $48.79 exercise price | 2011-12-13 | |
| 2011-12-09 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +55,700 55,700 owned after | $48.79 exercise price | 2011-12-13 | |
| 2011-12-09 | Cohen Cheryl Officer (Chief Commercial Officer) | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,800 17,800 owned after | $48.79 exercise price | 2011-12-13 | |
| 2011-12-09 | Hung David Director, Officer (President and CEO) | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +133,600 133,600 owned after | $48.79 exercise price | 2011-12-13 | |
| 2010-01-14 | BLICKENSTAFF KIM D Director | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 61,900 owned after | $3.75 exercise price | 2010-01-15 | |
| 2008-09-11 | BLICKENSTAFF KIM D Director | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 81,900 owned after | $3.75 exercise price | 2008-09-11 | |
| 2007-07-20 holding as of filing | CHAKRAVARTY SARVAJIT Officer (VP of Medicinal Chemistry) | 3 | No securities owned Non-derivative · Direct | Holding | 0 owned after | no price filed | 2007-07-20 | |
| 2006-09-15 holding as of filing | Protter Andrew A Officer (VP, Preclinical Development) | 3 | No securities owned. Non-derivative · Direct | Holding | 0 owned after | no price filed | 2006-09-15 | |
| 2006-07-18 holding as of filing | VERNON W ANTHONY Director | 3 | No securities owned. Non-derivative · Direct | Holding | 0 owned after | no price filed | 2006-07-18 |